Biomarin Pharmaceutical Inc Reaffirms FY 2013 Revenue Guidance; Raises Prior FY 2013 Earnings Guidance


Thursday, 25 Jul 2013 05:00pm EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenues in $530 million to $555 million range, expects GAAP loss forecast of $(185) to $(160) million and non-GAAP adjusted EBITDA $(65) to $(40) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $545 million and net income of $(176) million for fiscal 2013. 

Related Company News

Company Quote

71.22
1.6 +2.30%
29 Aug 2014